Longfellow Investment Management Co. LLC Makes New Investment in AstraZeneca PLC $AZN

Key Points

• Longfellow Investment Management Co. LLC purchased a new stake of 49,765 shares of AstraZeneca (NASDAQ:AZN) in Q3, valued at about $3.818 million, making AZN roughly 0.9% of its portfolio and its 17th-largest holding.
• Analysts' consensus is a Moderate Buy (nine Buy ratings, one Sell) with a consensus price target of $95.75 for AstraZeneca.
• AstraZeneca announced a dividend of $1.595 per share payable on March 23 (ex-dividend date February 20), with a reported dividend payout ratio of 66.26%.

Longfellow Investment Management Co. LLC purchased a new stake in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 49,765 shares of the company's stock, valued at approximately $3,818,000. AstraZeneca comprises about 0.9% of Longfellow Investment Management Co. LLC's portfolio, making the stock its 17th largest position.

A number of other hedge funds also recently modified their holdings of the business. NewSquare Capital LLC increased its holdings in AstraZeneca by 149.3% in the second quarter. NewSquare Capital LLC now owns 364 shares of the company's stock valued at $25,000 after purchasing an additional 218 shares during the period. Rakuten Investment Management Inc. bought a new stake in shares of AstraZeneca in the 3rd quarter valued at about $31,000. FSA Wealth Management LLC increased its stake in shares of AstraZeneca by 376.0% in the second quarter. FSA Wealth Management LLC now owns 476 shares of the company's stock valued at $33,000 after buying an additional 376 shares during the period. VSM Wealth Advisory LLC bought a new position in shares of AstraZeneca during the second quarter worth about $33,000. Finally, E Fund Management Hong Kong Co. Ltd. raised its position in shares of AstraZeneca by 144.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 466 shares of the company's stock worth $36,000 after acquiring an additional 275 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on AZN shares. Deutsche Bank Aktiengesellschaft reissued a "sell" rating on shares of AstraZeneca in a research report on Friday, February 6th. Wall Street Zen cut shares of AstraZeneca from a "strong-buy" rating to a "buy" rating in a research report on Saturday, January 17th. TD Cowen reissued a "buy" rating on shares of AstraZeneca in a research note on Tuesday, December 9th. Weiss Ratings reaffirmed a "buy (b)" rating on shares of AstraZeneca in a research report on Wednesday, January 21st. Finally, Guggenheim reiterated a "buy" rating on shares of AstraZeneca in a report on Wednesday, December 3rd. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, AstraZeneca presently has a consensus rating of "Moderate Buy" and a consensus price target of $95.75.

AstraZeneca Stock Down 1.9%

AstraZeneca stock opened at $197.74 on Friday. The company has a market capitalization of $306.68 billion, a PE ratio of 65.69, a PEG ratio of 1.59 and a beta of 0.32. AstraZeneca PLC has a 12-month low of $122.48 and a 12-month high of $212.71. The firm's fifty day moving average is $144.68 and its 200 day moving average is $105.45. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54.

AstraZeneca Dividend Announcement

The company also recently announced a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be paid a $1.595 dividend. The ex-dividend date is Friday, February 20th. This represents a dividend yield of 156.0%. AstraZeneca's dividend payout ratio (DPR) is currently 66.26%.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden's Astra AB and the UK's Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca's operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.